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Antihypertensive and p-adrenoceptor antagonist action 
of timolol 
After a 4-wk placebo period, 20 patients with essential hypertension received incremental 
doses of timolol (20, 40, and 60 mg daily) during three consecutive 3-wk treatment 
periods. Throughout the study, home blood pressures (BP) were obtained twice daily. At 
the end of each study period, plasma renin activity (PRA), the maximum heart rate (RR) 
response to isoproterenol (30 ng Ikg Imin) and to ergometric exercise (750 to 1,050 
kgmlmin), and serum timolollevels were measured. Average weekly home BP of 1501100 
on placebo fell to 139193 on 20 mg of timolol (p < 0.01 ). An additional fall in diastolic 
BP (4 mm Hg, p < 0.01) occurred as the dose was increased to 60 mg. PRA, 2.6 
ng Iml Ihr on placebo decreased to 1.2 on 20 mg of timolol (p < 0.05); thereafter it did 
not change. The mean maximum heart rates in response to isoproterenol and exercise 
were 117 and 158 beats/min on placebo; the maximum rates were 64 and 112 when the 
patients were receiving 20 mg of tim 0101 (p < 0.001). On 60 mg, mean maximum heart 
rates decreased to 57 with isoproterenol and to 104 with exercise (p < 0.02). Timolol, 
20, 40, and 60 mg daily, resulted in a wide range but increasing serum concentrations of 
the drug. The antihypertensive effect of timolol did not correlate with the fall in PRA. 
PRA and the maximum HR response to isoproterenol on placebo did not predict the BP 
response to timolol. That PRA was not predictive of the BP response cannot be taken as 
conclusive because of small number of low renin patients (3) in our series. 
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Timolol maleate, a beta adrenoceptor an-
tagonist, has been shown to be an effective an-
tihypertensive agent. I, 6, 10, 11 It is a pure, non-
selective adrenoceptor antagonist without 
membrane-stablizing or sympathomimetic ac-
tivity. On a weight for weight basis, it is 8 to 10 
times as potent as propranolol. The average ef-
fective daily antihypertensive dosage of the 
drug is 21 mg with a range of 15 to 30 mg. 
In our study, patients with mild or moderate 
essential hypertension were given timolol alone 
as the only drug for their hypertension. To de-
termine the antihypertensive efficacy of increas-
ing doses of timolol, a fixed dose schedule of 
20, 40, and 60 mg daily during 3 consecutive 
3-wk periods was followed. Home blood 
pressures were obtained to establish the onset of 
the antihypertensive action. The antihyperten-
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si ve response was related to the degree of beta 
inhibition and the changes in plasma renin ac-
tivity. The initial heart rate and the heart rate 
response to endogenous and exogenous sympa-
thetic stimulation and the renin status of patients 
were evaluated as predictors of the therapeutic 
response. 
Methods 
The subjects were 20 male patients, mean 
age, 39 (range, 23 to 56), with mild or moderate 
essential hypertension. Six of the subjects were 
black, and 14 white. The average known dura-
tion of hypertension was 7.4 yr (range, 4 mo to 
25 yr). Secondary causes of hypertension were 
excluded by clinical examination, rapid-
sequence intravenous pyelography, and labora-
tory studies (serum creatinine and potassium, 
urinanalysis, and urinary epinephrine and nor-
epinephrine). None of the subjects had coronary 
heart disease, valvular heart disease, a history 
of cerebrovascular disease, a history of conges-
tive heart failure, bundle branch block, atrio-
ventricular block, chronic obstructive lung 
disease, a history of bronchial asthma, allergic 
rhinitis, renal insufficiency (serum creatinine 
above 1. 9 mgt dl) or grade III or IV hyperten-
sive retinopathy. 
All antihypertensive medications were dis-
continued, and all subjects were given placebo, 
one tablet twice daily for 4 wk, followed by 3 
consecutive 3-wk periods of incremental doses 
of timolol, 20, 40, and 60 mg daily, in two 
divided doses. Casual sitting home blood 
pressures, twice daily, were obtained and aver-
aged weekly throughout the study. The subjects 
were seen at the end of the placebo period and at 
the end of each 3-wk treatment period, when the 
following measurements were made: 
Vital signs. Clinic sitting blood pressures and 
heart rates were taken by the same nurse 
throughout the study. 
Plasma renin activity (PRA). Blood for 
PRA determination was drawn between 9 to 11 
A.M. after the subjects were standing and walk-
ing for 1 hr. PRA was determined by radioim-
munoassay of angiotensin I according to the 
method of Haber and co-workers. 8 PRA values 
were related to the urinary sodium excretion 
Antihypertensive action of tim%l 153 
during the 24-hr period that preceded the draw-
ing of blood. 5 
Heart rate response to isoproterenol infu-
sion. After 10 min of supine rest, isoproterenol, 
30 ng base/kg/min, was administered for 12 
min into an antecubital vein from a constant-
infusion pump. The heart rate response to iso-
proterenol was recorded electrocardiographical-
ly, and the maximum heart rate achieved during 
the infusion was obtained. 
Heart rate response to ergometric exercise. 
For each subject, the ergometer was set at a 
constant load, which was shown prior to the 
study to produce a heart rate of at least 150 
beats/min after 2-min exercise. The average 
load in the 20 subjects was 960 kgm/min 
(range, 750 to 1,050). The maximum heart rate 
at the end of 2-min exercise was obtained from 
a IS-sec strip of the electrocardiogram. 
Serum timolol concentrations. In 15 sub-
jects, blood for serum timolol levels was ob-
tained at the end of each 3- wk treatment period. 
Blood was drawn between 9 and 11 A.M., 2 to 4 
hrs after the morning dose of timolol. The 
serum was separated by centrifugation and 
stored at -210 C before being sent for analysis. 
Serum timolol concentration was measured by 
the electron-capture gas chromatographic 
method. * 
Student's t test, the t test for paired observa-
tions and correlation coefficients were calcu-
lated by means of the Midas (Constat) computer 
program of the Statistical Research Laboratory 
at the University of Michigan. 
Results 
The average weekly home blood pressures 
for the last week of each study period and the 
clinic blood pressures are listed in Table I. Av-
erage weekly home and clinic blood pressures, 
150/100 and 151/102 on placebo, fell to 139/93 
and 135/94 on 20 mg of timolol (p < 0.01). 
An additional fall in the average home diastolic 
blood pressures occurred in every subject dur-
ing the next 6 wk as the dose of timolol was 
increased to 40 and then to 60 mg. Average 
clinic blood pressures remained unchanged as 
'Courtesy of Merck, Sharp & Dohme Research Laboratories. 
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Table I, Mean (±SEM) weekly home* and clinic blood pressures of 20 hypertensive subjects 






150 ± 2.9 
100 ± 2.0 
151 ± 4.6 
102 ± 2.6 
p value 






139 ± 2.4 
93 ± 2.1 
135 ± 3.7 




136 ± 2.7 
89 ± 2.1 
136 ± 4.4 
93 ± 2.9 
1 60 
136 ± 3.1 
89 ± 2.4 
137 ± 3.6 
94 ± 2.7 
p value 





* Mean weekly home blood pressure during the last week of each study period is shown. 
Table II. Mean (±SEM) weekly blood pressures of 14 responders* to the 





148 ± 4.0 
100 ± 2.2 
p value 




134 ± 2.4 




132 ± 3.2 
87 ± 2.7 
I 60 
130 ± 2.5 
86 ± 2.4 
p value 
(20 vs 60 mg) 
<0.05 
<0.01 
* Defined as 2: 10 mm Hg fall in mean arterial blood pressure at home on 60 mg of timolol compared with values on placebo. 
the dose of timolol was increased. In 14 sub-
jects, defined as responders, mean arterial blood 
pressures at home were reduced by 10 mm Hg 
or more at the end of the study. The pattern of 
home blood pressure responses to increasing 
doses of timolol in responders was similar to 
that of the group as a whole, except that a small 
additional decrease also occurred in systolic 
blood pressures as the dose of timolol was in-
creased from 20 to 60 mg (Table II). 
In 14 subjects, the records of the twice-daily 
home blood pressures were sufficiently com-
plete to allow a day-by-day analysis of the 
blood pressure response to 20 mg of timolol. 
The average home blood pressure at the end of 
the placebo period, 150/104, fell to 142/96 
(p < 0.05) by the end of the first day and to 
139/95 (p < 0.01) by the end of the second day 
of treatment. The average home blood pressure 
by the end of the first week of therapy with 20 
mg of timolol was 136/92 (p < 0.001). There 
was no additional antihypertensive effect of 20 
mg of timolol in these subjects during the re-
maining 2 wk of treatment. 
Average clinic sitting and isoproterenol- and 
exercise-induced heart rates are summarized in 
Table III. Sitting heart rates, 74 ± 1.9 
(mean ± SEM) on placebo, were reduced to 
63 ± 1.6 on 20 mg of timolol (p < 0.001). 
There was no further decrease in sitting heart 
rate as the dose of timolol was increased. The 
mean maximum heart rates in response to a 
fixed dose of isoproterenol and to a fixed exer-
cise load, 117 and 158 beats/min (mean) on 
placebo, were reduced to 64 and 112 on 20 mg 
of timolol (p < 0.001). On 60 mg of timolol, 
heart rate decreased to 57 on isoproterenol and 
to 105 on exercise (p < 0.02). 
Based on a nomogram, derived in our labo-
ratories, relating plasma renin activity (PRA) 
to 24-hr urinary excretion, PRA on placebo 
was low in 3, normal in 12, and high in 5 sub-
jects. 8 The plasma renin activities of our sub-
jects, 2.6 ± 0.51 ng/ml/min (mean ± SEM, 
N = 20) on placebo, was reduced (p < 0.05) 
to 1.2 ± 0.25, 1.4 ± 0.31, and 1.3 ± 0.24, 
respectively, on 20, 40 and 60 mg of timolol. 
In 15 subjects, mean ± SEM serum timolol 
levels (ng/ml) on 20, 40, and 60 mg of timolol 
were: 42 ± 7.0 (range, 0 to 86), 77 ± 10.8 
(range, 30 to 156), and 96 ± 12.6 (range, 39 to 
171). Five of the 15 subjects were nonrespond-
ers to the antihypertensive effect of timolol. 
Serum timolollevels on 20, 40, and 60 mg of 
the drug, 36, 82, and 109 ng/ml (mean), were 
similar to those of the group as a whole. With 
one exception, a high degree of beta adrenergic 
inhibition was achieved with 20 mg of timolol 
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Table III. Mean (±SEM) sitting and isoproterenol and exercise-induced 







74 ± 1.9 
117 ± 3.8 
158 ± 2.3 
p value 





63 ± 1.6 
64 ± 2.7 




63 ± 1.8 
60 ± 1.2 
107 ± 2.1 
I 60 
61 ± 1.3 
57 ± 1.2 
105 ± 2.0 
p value 




*' Mean maximum heart rates <?btained in response to isoproterenol and exercise are shown. 
tMean supine heart rates before isoproterenol infusion were: 73 ± 2.5, 59 ± 1.5, 58 ± 1.3, and 56 ± 1.3 on placebo and 20, 40, and 60 
mg of timolo!' 
Table IV. Comparisons of mean (±SEM) weekly home blood pressures, sitting and 
isoproterenol- and exercise-induced heart rates, and plasma renin activities of responders 
(N = 14) and of nonresponders (N = 6) on placebo and on 20 mg of timolol 
Placebo Timolol (20 mg) 
Parameter Responders I Nonresponders Responders I Nonresponders 
Home blood pressure 148 ± 4.0 153 ± 3.2 134 ± 2.4 149±3.1* 
(mm Hg) 100 ± 2.2 99 ± 4.3 90 ± 2.3 99 ± 4.0t 
Heart rate (beats/ min) 
Sitting 75 ± 2.1 72 ± 4.2 63 ± 2.1 64 ± 2.4 
Isoproterenolt 117 ± 3.6 116 ± 10.4 62 ± 1.7 69 ± 8.2 
Exerciset 158 ± 2.5 156 ± 5.2 III ± 2.7 114 ± 4.4 
Plasma renin activity 3.0 ± 0.63 1.4 ± 0.47 1.5 ± 0.31 0.7 ± 0.15 
(ng/ml/hr) 
*p < 0.01 for comparisons of values in responders and nonresponders. 
tp < 0.05 for comparisons of values in responders and nonresponders. 
:j:Mean maximum heart rates obtained in response to isoproterenol and exercise are shown. 
in the 15 subjects despite variations in serum 
timolol levels. In the only subject with an un-
measurable serum timolol level, the heart rate 
rose to 108 beats/min with isoproterenol and to 
126 with exercise. There were no statistically 
significant correlations between the serum con-
centration of drug and degree of beta adrenergic 
inhibition. 
Finally, the home blood pressure, the heart 
rate, and the PRA responses to 20 mg of timolol 
of responders and of nonresponders were com-
pared (Table IV). At the end of placebo period, 
the two groups were comparable with regard to 
blood pressure and heart rate responses. The 
numeric difference in the average PRA of re-
sponders and of nonresponders during the 
placebo period did not achieve statistical 
significance (p > 0.1). During treatment with 
20 mg of timolol, there was a similar reduction 
in sitting and isoproterenol- and exercise-
induced heart rates and in PRA in responders 
and nonresponders. The change in mean arterial 
blood pressure between placebo and 20 mg of 
timolol was unrelated to the change in PRA in 
both the entire group of subjects (r = 0.14, 
N = 20) and in responders (r = 0.09, N = 14). 
There was no reduction in blood pressure by 20 
mg of timolol in all 3 low renin hypertensive 
subjects. When the dose of timolol was raised to 
60 mg, 2 of the low renin hypertensive subjects 
responded. 
Discussion 
In this group of patients with mild to 
moderate essential hypertension, the principal 
antihypertensive effect of timolol, 73% of the 
total reduction in the average mean arterial 
blood pressure, occurred with 20 mg of timolol 
daily, the lowest dose schedule. Further 
analysis of the home blood pressures showed 
that the reduction in mean arterial blood 
pressure due to 20 mg of timolol was complete 
156 Simon, Kiowski, and Julius 
at the end of the first week and that there had 
been a significant reduction in blood pressure by 
the end of the first day. It appears that the he-
modynamic adjustments that account for the 
antihypertensive effect of timolol are complete 
within the first few days of the administration of 
an effective beta inhibitor dose. The small ad-
ditional antihypertensive effect of 40 and 60 mg 
of timolol seems to be related to the enlarge-
ment of the dose rather than to the long-term 
hemodynamic adjustments to the initial 20-mg 
dose. 
During treatment with 20 mg of timolol, 
clinic sitting heart rates and plasma renin ac-
tivities reached their lowest level. The heart rate 
response to a fixed dose of isoproterenol and to 
a fixed load of exercise was reduced 88% and 
87% of the maximum reduction achieved with 
60 mg of timolol. A small additional beta 
adrenoceptor-inhibiting effect of timolol was 
noted as the dose was increased to 40 and 60 mg 
daily. This finding accords with the receptor 
theory of drug antagonism. Similar degrees of 
beta inhibition were achieved in the blood 
pressure responders and the nonresponders by 
the three dose levels used. Beta adrenoceptor 
inhibition, therefore, is not the only determinant 
of the antihypertensive action of timolol. 
A theory of dual antihypertensive action of 
beta adrenoceptor antagonists has been pro-
posed. 9 According to this theory, the first and 
principal antihypertensive effect occurs with 
low serum concentrations and is associated with 
the drug's renin-lowering properties. The sec-
ond effect requires higher serum concentrations 
and is not related to an additional lowering of 
plasma renin activity. The findings of this study 
support the observation of an additional an-
tihypertensive effect of the higher doses of a 
beta adrenoceptor antagonist drug. 
There was no correlation between the an-
tihypertensive and the renin-lowering effect of 
20 mg of timolol, but the study was not de-
signed to investigate such a relationship. The 
initial dose of timolol was probably in excess of 
that required to suppress renin, resulting 
perhaps in an antihypertensive effect unrelated 
to the reduction in plasma renin activity. The 
number of patients (3 in all) with low renin 
hypertension was small. 
It has been suggested that hypertensive pa-
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tients with a hyperkinetic circulation, charac-
terized in part by an increased resting heart rate 
and an increased cardioaccelerator response to 
the intravenous infusion of a beta adrenoceptor 
agonist, are more likely to respond with a re-
duction in blood pressure to a beta adrenoceptor 
antagonist drug. 7 BUhler and co-workers2 have 
reported that hypertensive patients with high 
PRA exhibit favorable blood pressure responses 
to low to moderate doses of propranolol, 
whereas patients with low renin hypertension 
exhibit a negligible blood pressure response. In 
our study, 2 the resting heart rate and the heart 
rate response to isoproterenol while our patients 
were on placebo were of no value in predicting 
the blood pressure response to timolol. At the 
end of the placebo period, the PRA of respond-
ers was twice that of nonresponders but the 
difference was not statistically significant. Had 
we enlarged our series and included more pa-
tients with low renin hypertension, the differ-
ence in baseline PRA of responders and nonres-
ponders might have reached statistical 
significance and confirmed the reports of Buhler 
and colleagues,2 and of others. 9 
Timolol, 20, 40, and 60 mg, resulted in a 
wide range of serum concentrations of the drug, 
but the average values increased with each in-
crement in dosage. The wide range of serum 
concentrations can be accounted for in part by 
the variable time interval (2 to 4 hr) between the 
morning dose of the drug and the drawing of 
blood for the serum concentration mea-
surements. Serum concentrations of the drug 
did not seem to bear a relationship to either the 
degree of beta adrenoceptor inhibition or the 
antihypertensive effect of the drug. The wide 
range of serum timolol levels and the high de-
gree of beta adrenergic inhibition achieved with 
20 mg of timolol were probably responsible for 
the lack of correlation between the drug levels 
and the degrees of beta adrenergic inhibition. 
A more complete study of serum concentra-
tions, which would permit calculation of the 
area under the time-concentration curve, might 
have revealed a correlation between the serum 
concentrations of drug and pharmacologic ef-
fect. There were no data in the literature with 
which to compare our values of serum timolol 
concentrations. 
The design of this study evoked a comparison 
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of beta inhibition by isoproterenol infusion and 
by exercise. Exercise, an endogenous sympa-
thetic stimulus, inducing heart rate responses 
above 130 beats/min during a placebo period, 
has been the preferred test of the degree of beta 
inhibition achieved with beta adrenoceptor an-
tagonists. 3 Isoproterenol-induced tachycardia, 
an exogenous sympathetic stimulus, also has 
been used and is most accurate when a dose-
response curve is established. 4 In our study, no 
attempt was made to establish a dose-response 
curve for exogenous beta stimulation. The re-
sults obtained with isoproterenol were similar to 
those achieved with exercise testing at all three 
dose levels of timolol. 
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